Developer docs
API playgroundTry for free, no card

Search company profiles

General Fluidics

Full company profile

uuid0000z5k

Namestring
General Fluidics
Legal namestring
General Fluidics Corporation
Company typeenum
Private
Founded yearint
2014
Descriptiontext

General Fluidics Corporation is a privately held in vitro diagnostics company founded in 2014 and headquartered in Waltham, Massachusetts (Delaware-incorporated). The company develops the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." Axess is a compact benchtop system that integrates three gold-standard analytical technologies — hematology, clinical chemistry, and immunoassay — into a single device, paired with low-cost programmable cartridges that support standard, consolidated, and custom test panels. The platform is designed to deliver reference-laboratory-quality blood diagnostic results in minutes at the point of care rather than requiring sample transport to centralized labs with multi-day turnaround.

The business model is a classic razor-and-blade hardware-plus-consumable structure: Axess instruments are placed at clinics, urgent care centers, and rural healthcare settings, with recurring revenue from consumable cartridges across a broad test menu. Go-to-market is direct enterprise sales to healthcare providers. Commercial scaling and regulatory clearance are being supported through a June 2026 strategic partnership with Invetech, selected after a multi-continent search for its three decades of FDA/CE medical device manufacturing experience.

General Fluidics has raised approximately $34.6 million in cumulative venture funding across rounds in 2018 (~$5.4M), 2021 (~$6.65M), and mid-2024 ($22.6M Series B plus a separate SEC Form D exempt offering targeting ~$27.9M with ~$18.5M already sold). The leadership team — including President & CEO Robert Granier, CFO Robert Warren, VP of Assay Development Terry Walker, VP of Engineering Etienne Dano, and VP of Product Management & Quality David Dolinger — collectively brings over 100 years of IVD product development and commercialization experience. Co-founder Kenneth Kotz is also identified. The company is pre-revenue with no FDA/CE clearances yet disclosed.

Short descriptiontext

General Fluidics develops the Axess™ point-of-care diagnostic platform, integrating hematology, clinical chemistry, and immunoassay on a single benchtop instrument with programmable cartridges to deliver reference-lab-quality blood results in minutes for clinics, urgent care centers, and rural healthcare settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, blood diagnostic testing, in vitro diagnostics, clinical chemistry analyzers, hematology immunoassay systems
Industry3 codes
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAA
Clinical Chemistry & Immunoassay Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Point-of-Care Diagnostic Platform Sales
TypeHardware Sales
Description

Sale of Axess diagnostic instruments and consumable cartridges to healthcare facilities including clinics, urgent care centers, and rural settings. The platform uses low-cost programmable cartridges which likely represent recurring consumable revenue.

generalfluidics.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Axess
Description

Point-of-care diagnostic testing platform integrating hematology, clinical chemistry and immunoassay technologies for blood diagnostics at the point of care

generalfluidics.com
Core offering1 text field

General Fluidics develops the Axess point-of-care diagnostic platform, a compact benchtop system that integrates three gold-standard analytical technologies—hematology, clinical chemistry, and immunoassay—into a single instrument paired with low-cost programmable cartridges. The platform delivers reference-laboratory quality blood and urine diagnostic results in minutes at the point of care, targeting clinics, urgent care centers, and rural healthcare settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Blood diagnostic results delivered in minutes rather than days
+1 more record
Product overview1 text field

General Fluidics offers a single unified product—the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." The platform integrates three gold-standard analytical technologies (hematology, clinical chemistry, and immunoassay) into a single compact benchtop system with low-cost programmable cartridges, enabling full test menus at the point of care rather than requiring samples to be sent to reference laboratories.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Invetech serves as General Fluidics' development and scaleup partner for the Axess point-of-care diagnostic platform. After a global search spanning four continents, GF selected Invetech for its end-to-end manufacturing capability and three decades of experience developing FDA and CE-approved medical devices. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings, with results available within minutes at point of care.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

EKF offers POC chemistry, hemoglobin, and diabetes diagnostics for clinics and near-patient testing—a smaller but direct POC diagnostic peer in ambulatory settings.

TypeEmerging player
Description

Randox produces compact clinical chemistry analyzers (e.g., Evidence) and POC reagents aimed at decentralized testing—an adjacent competitor serving clinics and urgent care.

3Abbott Laboratories (i-STAT / Piccolo)
TypeDirect peer
Description

Abbott's i-STAT and Piccolo systems are the dominant handheld/benchtop point-of-care blood diagnostic platforms, directly competing with Axess in clinical chemistry, immunoassay, and hematology at the point of care.

TypeBroad incumbent
Description

Roche operates cobas and other POC platforms spanning clinical chemistry and immunoassay, serving the same clinic and hospital customers as General Fluidics with broader menu and global reach.

TypeDirect peer
Description

Siemens' epoc blood analysis system delivers POC clinical chemistry and immunoassay results, competing head-to-head with Axess for urgent care and clinic placements.

TypeDirect peer
Description

Nova manufactures Stat Profile and Nova Prime POC analyzers used for blood gas, chemistry, and critical care testing—directly comparable POC diagnostic modality and customer base.

TypeBroad incumbent
Description

QuidelOrtho offers Triage and Sofia POC immunoassay and rapid diagnostics, plus central lab products—an established competitor across the menu categories GF targets.

TypeDirect peer
Description

Sysmex is a global leader in hematology analyzers, including POC/compact hematology systems—competing directly with Axess's hematology capability in clinics and smaller labs.

TypeEmerging player
Description

Boule produces compact hematology analyzers (Swelab, Medonic) targeted at decentralized and small-lab settings—comparable customer segment and hematology focus.

TypeEmerging player
Description

HemoCue specializes in POC hemoglobin and blood component testing, often used in primary care and rural settings—an adjacent POC diagnostics competitor with overlapping end users.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

General Fluidics

Point-of-Care Diagnosticsgeneralfluidics.com

General Fluidics develops the Axess™ point-of-care diagnostic platform, integrating hematology, clinical chemistry, and immunoassay on a single benchtop instrument with programmable cartridges to deliver reference-lab-quality blood results in minutes for clinics, urgent care centers, and rural healthcare settings.

What General Fluidics does

General Fluidics Corporation is a privately held in vitro diagnostics company founded in 2014 and headquartered in Waltham, Massachusetts (Delaware-incorporated). The company develops the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." Axess is a compact benchtop system that integrates three gold-standard analytical technologies — hematology, clinical chemistry, and immunoassay — into a single device, paired with low-cost programmable cartridges that support standard, consolidated, and custom test panels. The platform is designed to deliver reference-laboratory-quality blood diagnostic results in minutes at the point of care rather than requiring sample transport to centralized labs with multi-day turnaround.

The business model is a classic razor-and-blade hardware-plus-consumable structure: Axess instruments are placed at clinics, urgent care centers, and rural healthcare settings, with recurring revenue from consumable cartridges across a broad test menu. Go-to-market is direct enterprise sales to healthcare providers. Commercial scaling and regulatory clearance are being supported through a June 2026 strategic partnership with Invetech, selected after a multi-continent search for its three decades of FDA/CE medical device manufacturing experience.

General Fluidics has raised approximately $34.6 million in cumulative venture funding across rounds in 2018 (~$5.4M), 2021 (~$6.65M), and mid-2024 ($22.6M Series B plus a separate SEC Form D exempt offering targeting ~$27.9M with ~$18.5M already sold). The leadership team — including President & CEO Robert Granier, CFO Robert Warren, VP of Assay Development Terry Walker, VP of Engineering Etienne Dano, and VP of Product Management & Quality David Dolinger — collectively brings over 100 years of IVD product development and commercialization experience. Co-founder Kenneth Kotz is also identified. The company is pre-revenue with no FDA/CE clearances yet disclosed.

General Fluidics firmographics

Firmographics
Name
General Fluidics
Legal name
General Fluidics Corporation
Website
https://generalfluidics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
General Fluidics develops the Axess™ point-of-care diagnostic platform, integrating hematology, clinical chemistry, and immunoassay on a single benchtop instrument with programmable cartridges to deliver reference-lab-quality blood results in minutes for clinics, urgent care centers, and rural healthcare settings.
Ownership category
akta.pro rank

General Fluidics industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAA
Clinical Chemistry & Immunoassay Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Point-of-care diagnostics
  • Blood diagnostic testing
  • In vitro diagnostics
  • Clinical chemistry analyzers
  • Hematology immunoassay systems

Where General Fluidics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

General Fluidics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Point-of-Care Diagnostic Platform Sales: Sale of Axess diagnostic instruments and consumable cartridges to healthcare facilities including clinics, urgent care centers, and rural settings. The platform uses low-cost programmable cartridges which likely represent recurring consumable revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

General Fluidics product offering

Product offering

Core offering

General Fluidics develops the Axess point-of-care diagnostic platform, a compact benchtop system that integrates three gold-standard analytical technologies—hematology, clinical chemistry, and immunoassay—into a single instrument paired with low-cost programmable cartridges. The platform delivers reference-laboratory quality blood and urine diagnostic results in minutes at the point of care, targeting clinics, urgent care centers, and rural healthcare settings.

Product overview

General Fluidics offers a single unified product—the Axess™ point-of-care diagnostic platform, marketed as "The Point of Care Laboratory™." The platform integrates three gold-standard analytical technologies (hematology, clinical chemistry, and immunoassay) into a single compact benchtop system with low-cost programmable cartridges, enabling full test menus at the point of care rather than requiring samples to be sent to reference laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • Axess: Point-of-care diagnostic testing platform integrating hematology, clinical chemistry and immunoassay technologies for blood diagnostics at the point of care

Quantifiable outcome

  • Blood diagnostic results delivered in minutes rather than days
  • +1 more outcomes

Companies that use General Fluidics

Customer profile

Segments3 records

Ideal customer profiles1 record

General Fluidics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

General Fluidics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • InvetechcoreStrategic or Co-development Partner · 4 June 2026Invetech serves as General Fluidics' development and scaleup partner for the Axess point-of-care diagnostic platform. After a global search spanning four continents, GF selected Invetech for its end-to-end manufacturing capability and three decades of experience developing FDA and CE-approved medical devices. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings, with results available within minutes at point of care.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

General Fluidics competitors and assessment

Company assessment

Emerging players

  • EKF Diagnostics: EKF offers POC chemistry, hemoglobin, and diabetes diagnostics for clinics and near-patient testing—a smaller but direct POC diagnostic peer in ambulatory settings.
  • Randox Laboratories: Randox produces compact clinical chemistry analyzers (e.g., Evidence) and POC reagents aimed at decentralized testing—an adjacent competitor serving clinics and urgent care.
  • Boule Diagnostics: Boule produces compact hematology analyzers (Swelab, Medonic) targeted at decentralized and small-lab settings—comparable customer segment and hematology focus.
  • HemoCue: HemoCue specializes in POC hemoglobin and blood component testing, often used in primary care and rural settings—an adjacent POC diagnostics competitor with overlapping end users.

Direct peers

  • Abbott Laboratories (i-STAT / Piccolo): Abbott's i-STAT and Piccolo systems are the dominant handheld/benchtop point-of-care blood diagnostic platforms, directly competing with Axess in clinical chemistry, immunoassay, and hematology at the point of care.
  • Siemens Healthineers (epoc / RAPIDPoint): Siemens' epoc blood analysis system delivers POC clinical chemistry and immunoassay results, competing head-to-head with Axess for urgent care and clinic placements.
  • Nova Biomedical: Nova manufactures Stat Profile and Nova Prime POC analyzers used for blood gas, chemistry, and critical care testing—directly comparable POC diagnostic modality and customer base.
  • Sysmex: Sysmex is a global leader in hematology analyzers, including POC/compact hematology systems—competing directly with Axess's hematology capability in clinics and smaller labs.

Broad incumbents

  • Roche Diagnostics: Roche operates cobas and other POC platforms spanning clinical chemistry and immunoassay, serving the same clinic and hospital customers as General Fluidics with broader menu and global reach.
  • QuidelOrtho: QuidelOrtho offers Triage and Sofia POC immunoassay and rapid diagnostics, plus central lab products—an established competitor across the menu categories GF targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

General Fluidics social profiles

Digital presence

General Fluidics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

General Fluidics leadership team

Management profile

Number of profiles

Profiles6 records

General Fluidics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

General Fluidics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Fluidics

What does General Fluidics do?

General Fluidics develops the Axess point-of-care diagnostic platform, a compact benchtop system that integrates three gold-standard analytical technologies—hematology, clinical chemistry, and immunoassay—into a single instrument paired with low-cost programmable cartridges. The platform delivers reference-laboratory quality blood and urine diagnostic results in minutes at the point of care, targeting clinics, urgent care centers, and rural healthcare settings.

Is General Fluidics a public or private company?

General Fluidics is a private company. It is classified as venture growth investor backed and is currently operating.

When was General Fluidics founded?

General Fluidics was founded in 2014. It employs 11 to 50 people.

Where is General Fluidics based?

General Fluidics is headquartered in Watertown, United States, in the North America region.

How does General Fluidics make money?

One revenue line is on record: point-of-Care Diagnostic Platform Sales.

Who are General Fluidics's main competitors?

Emerging players on record are EKF Diagnostics, Randox Laboratories, Boule Diagnostics and HemoCue. Direct peers are Abbott Laboratories (i-STAT / Piccolo), Siemens Healthineers (epoc / RAPIDPoint), Nova Biomedical and Sysmex. Broad incumbents are Roche Diagnostics and QuidelOrtho.

Does General Fluidics have an API?

No public API is recorded for General Fluidics.

What industry is General Fluidics in?

General Fluidics's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics), with a secondary code of HLAHAAAA, Clinical Chemistry & Immunoassay Systems. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BriefglanceThe Quiet Revolution: How a New Partnership Aims to Reinvent Your VisitDiagnostic innovator General Fluidics and development firm Invetech have announced a strategic partnership to accelerate deployment of the Axess platform, a compact benchtop system capable of delivering blood diagnostic results in minutes rather than days, targeting the decentralization of routine lab testing. The collaboration arrives as the global point-of-care diagnostics market is projected to more than double from $43 billion in 2024 to nearly $88 billion by 2032. General Fluidics has raised $34.6 million to date, including a $22.6 million Series B round in mid-2024, while Invetech brings three decades of experience developing FDA and CE-approved medical devices to guide the platform through regulatory approval and scale manufacturing.PR NewswireGeneral Fluidics and Invetech Partner to Accelerate Accessible Diagnostics at the Point of CareGeneral Fluidics and Invetech announced a strategic collaboration on June 4, 2026, with Invetech serving as General Fluidics' development and scaleup partner for its Axess point-of-care diagnostic platform. After a global search spanning four continents, GF selected Invetech for its end-to-end manufacturing capability and diagnostics expertise. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings, with results available within minutes at point of care.SecSEC FORM DGeneral Fluidics Corp filed a Form D with the SEC on July 31, 2024, announcing an exempt securities offering that began sales on July 16, 2024. The company has sold $18.5 million of its $27.9 million total offering target to 16 investors so far.